Business Context and Reporting Period
This Form 8-K is a Current Report filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 9, 2009. The filing serves as a Regulation FD disclosure regarding an investor conference call held on the same date to provide an update on the Company's recombinant protective antigen anthrax vaccine program.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the dissemination of qualitative updates regarding the anthrax vaccine program via an investor conference call.
Guidance, Outlook, and Risks
- Management Commentary: The Company hosted a conference call to update investors on its anthrax vaccine program. A transcript of this call is attached as Exhibit 99.1.
- Legal Disclaimer: The information in this report, including the attached transcript, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by reference.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this filing; investors are directed to other SEC documents for detailed information.
Key Facts for Investor Verification
- Verify the content of the December 9, 2009 investor conference call transcript (Exhibit 99.1) for specific details on the anthrax vaccine program status.
- Confirm that the registrant is PharmAthene, Inc., as the input metadata referenced Altimmune, Inc., which is incorrect based on the filing text.
- Note that this filing does not contain audited financial data; refer to the most recent 10-K or 10-Q for financial metrics.